SEC Form 4 · accession 0001209191-16-096061
NEKTAR THERAPEUTICS · NKTR
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Ivan P. Gergel
Officer — SVP & Chief Medical Officer
Period of report
Feb 3, 2016
Accepted (ET)
Feb 5, 2016 · 6:12 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000906709
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock OptionF1 | $12.21 | Feb 3, 2016 | A | 100,000 | A | — | Feb 2, 2024 | Common Stock | 100,000 | 100,000 | D |
Explanation of responses
- F1This stock option vests over a period of 4 years with 25% of the option vesting on the first anniversary of the grant date and the remaining 75% of the option in monthly installments over the 3-year period thereafter.